ALNY - Alnylam Pharmaceuticals Non-GAAP EPS of -$1.49 misses by $0.03 revenue of $213.26M misses by $29.56M; updates FY22 guidance

Alnylam Pharmaceuticals press release (NASDAQ:ALNY): Q1 Non-GAAP EPS of -$1.49 misses by $0.03. Revenue of $213.26M (+20.1% Y/Y) misses by $29.56M. Cash, cash equivalents and marketable securities were $2.24 billion as of March 31, 2022 compared to $2.44 billion as of December 31, 2021 with the decrease primarily due to our operating loss in the first quarter of 2022. 2022 Updated Financial Guidance: Net revenues from collaborations and royalties of $175M – $225M; Non-GAAP R&D and SG&A expenses of $1,390M – $1,450M.

For further details see:

Alnylam Pharmaceuticals Non-GAAP EPS of -$1.49 misses by $0.03, revenue of $213.26M misses by $29.56M; updates FY22 guidance